Aravive Inc to Discuss AVB-500 Phase 1b Study Updates Conference Call

20/11/2019 8:00

שיחת ועידה Aravive Inc

Aravive Inc Conference call will be held on 20/11/2019. During the earnings conference call's session Aravive Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Aravive Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing a novel long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency, or GHD, an orphan disease. A key limitation to current recombinant human growth hormone, or rhGH, products is that they impose the burden of daily injections over multiple years, often resulting in poor adherence, which in turn can lead to suboptimal treatment outcomes in GHD patients. Despite this limitation, global annual sales from currently marketed rhGH products have grown to more than $3 billion in 2015. Based on market research, we believe that the market for daily rhGH products can continue to grow up to $4 billion following the launch of long-acting rhGH therapies.    
קרא עוד שיחת ועידה

Aravive Inc (VSAR)

4200 Bohannon Drive, Menlo Park California 94025, United States